ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium

    Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

    Simone Melega 1, Paul Brogan2, Gavin Cleary 3, Aimee Hersh 4, Ozgur Kasapcopur 5, Satyapal Rangaraj 6, Rae Yeung 7, Andrew Zeft 8, Jennifer Cooper 9, Pooneh Pordeli 10, Petra Kirchner 11 and Patricia Lehane 12, 1F. Hoffmann-La Roche, Ltd., Basel, Switzerland, 2UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 3Alder Hey Children's Hospital, Liverpool, United Kingdom, 4University of Utah Primary Children's Hospital, Salt Lake City, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, 6Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, 7The Hospital for Sick Children, Toronto, Canada, 8The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, 9University of Colorado, Children's Hospital Colorado, Denver, 10F. Hoffmann-La Roche, Ltd., Mississauga, Canada, 11F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, 12Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
  • Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting

    Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US

    Robin Dore1, Jenya Antonova 2, Huan Huang 3, Lawrence Chang 2, Xin Wang 3 and Mark Genovese 4, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3IQVIA, Plymouth Meeting, PA, 4Stanford University, Stanford, CA

    Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…
  • Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting

    Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials

    Marina Magrey1, Victoria Navarro-Compán 2, Sandra Garces 3, Xenofon Baraliakos 4, David Sandoval 3, Jeffrey Lisse 3, Silvia Santisteban 3, David Adams 3, Fangyi Zhao 3 and Robert Inman 5, 1Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, 2University Hospital La Paz, IdiPaz, Madrid, Spain, 3Eli Lilly and Company, Indianapolis, IN, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5University of Toronto, University Health Network, Toronto, ON, Canada

    Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
  • Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting

    Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study

    Marianne Kerski1, Peter Boersma 2, Eric Miller 3, Ashley Brenner 4, Genevieve Melton 5 and Anna Shmagel 6, 1University of Minnesota Medical School, Minneapolis, MN, 2University of Minnesota School of Public Health, Minneapolis, 3University of Minnesota, Woodbury, MN, 4University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, 5University of Minnesota Department of Surgery, Minneapolis, MN, 6University of Minnesota, Minneapolis, MN

    Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
  • Abstract Number: 2095 • 2019 ACR/ARP Annual Meeting

    A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients

    Kieran Murray1, Candice Low 1, Francis Young 1, Anna O'Rourke 1, Ian Callanan 2, Eoin Feeney 1 and Douglas Veale 3, 1Saint Vincent's University Hospital, Dublin, Ireland, 2Saint Vincent's University Hospital, Dublin, Dublin, Ireland, 3EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland

    Background/Purpose: The ACR and CDC recommend influenza (“flu”) and 23-valent pneumococcal polysaccharide (PPSV23) vaccination for inflammatory arthritis (IA) patients on immunosuppression. This study aimed to:…
  • Abstract Number: 2103 • 2019 ACR/ARP Annual Meeting

    Anti-TNF Therapy in Patients with HIV Infection

    Joanna Marco1 and Alison Bays 2, 1University of Washington, Seattle, WA, 2University of Washington Division of Rheumatology, Seattle, WA

    Background/Purpose: Patients with Human Immunodeficiency Virus (HIV) infection may benefit from the use of anti-Tumor Necrosis Factor (TNF) therapy in the setting of inflammatory disease,…
  • Abstract Number: 2107 • 2019 ACR/ARP Annual Meeting

    Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database

    Eishi Uechi1 and Kiyohide Fushimi 2, 1Tomishiro Central Hospital, Tomigusuku city, Okinawa, Japan, 2Tokyo Medical and Dental University Graduate School, Bunkyo-ku, Tokyo, Japan

    Background/Purpose: Pneumonia is a common cause of death not only in the general population but also in patients with rheumatoid arthritis (RA). In particular, patients…
  • Abstract Number: 2109 • 2019 ACR/ARP Annual Meeting

    Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study

    Jaime Coral-Enriquez 1, Mauricio Restrepo 2, Gloria Vasquez 3, Carlos H Muñoz-Vahos 4, Daniel Jaramillo 5, Adriana Vanegas-García 4, Ruth Eraso 6, Johanna Hernández 7, Fabian Jaimes 8 and Luis Gonzalez2, 1Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, 2Grupo de Reumatología, Division of Rheumatology, Department of Internal Medicine, School of Medicine Universidad de Antioquia, Medellín, Colombia, 3University of Antioquia, Medellin, Antioquia, Colombia, 4Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, 5Rheumatology unit, Hospital Universitario San Vicente Fundación, Medellin, Colombia, 6Grupo de Reumatología, Universidad de Antioquia; Pediatric rheumatology unit, Hospital Pablo Tobón Uribe, Medellin, Colombia, 7Division of Rheumatology, Pediatric Department, School of Medicine, Universidad de Antioquia, Medellín, Colombia, 8Department of Epidemiology, Hospital Universitario San Vicente Fundación, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia

    Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have…
  • Abstract Number: 2122 • 2019 ACR/ARP Annual Meeting

    Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions

    Soumyasri Kambhatla1, Estefania Gauto-Mariotti 2 and Augustine Manadan 3, 1John H. Stroger Hospital of Cook County, Chicago, 2John H Stroger Hospital of Cook County, Chicago, IL, 3Rush University Medical Center, Chicago, IL

    Background/Purpose: Septic arthritis is known to cause significant morbidity due to joint destruction and mortality if timely and adequate treatment is not given. In this study,…
  • Abstract Number: 2125 • 2019 ACR/ARP Annual Meeting

    Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up

    mohammad hammad saied1, Liora Harel 2, Gil Amarilyo 3, rotem tal 4 and Razi Zidani 5, 1schneider medical center, kaboul village, Israel, 2Tel Aviv University, Tel Aviv, Israel, 3schneider medical center, petach tekva, 4schneider medical center, ramat gan, Israel, 5tel aviv university, Tamra, Israel

    Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
  • Abstract Number: 2521 • 2019 ACR/ARP Annual Meeting

    Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)

    Stephen McDonald1, Eoghan McCarthy 2, Aysun Aksoy 3, Ben Parker 4 and Ian Bruce 5, 1University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University Foundation Trust, The Kellgren Centre, Manchester, United Kingdom, Belfast, Northern Ireland, United Kingdom, 2Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, 3Marmara University Faculty of Medicine, Division of Internal Medicine, Department of Rheumatology, Istanbul, Turkey; University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom, Istanbul, Istanbul, Turkey, 4University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, 5University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom

    Background/Purpose: Mortality in Systemic Lupus Erythematosus (SLE) is increased compared to the general population. We sought to investigate mortality rates and associated factors in a…
  • Abstract Number: 2583 • 2019 ACR/ARP Annual Meeting

    Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies

    Chi Chiu Mok1, Kar Li Chan 2, Sau Mei Tse 2 and Ling Yin Ho 2, 1Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), 2Tuen Mun Hospital, Hong Kong, Hong Kong

    Background/Purpose: To study the prevalence of Herpes Zoster (HZ) reactivation in patients with biopsy confirmed lupus nephritis (LN) undergoing immunosuppressive therapies.Methods: Patients who had biopsy…
  • Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting

    Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study

    Ajinkya Pawar 1, Rishi Desai 1, Nileesa Gautam 1 and Seoyoung C. Kim2, 1Brigham and Women's hospital, Boston, 2Brigham and Women’s Hospital and Harvard Medical School, Boston

    Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…
  • Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting

    Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland

    Aron H Bjornsson1, Olafur Palsson 2, Mar Kristjansson 3, Petur S Gunnarsson 4, Gerdur Grondal 5, Bjorn Gudbjornsson 6 and Thorvardur J Love 7, 1Department of Medicine, Landspitali, Reykjavík, Iceland, 2Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden, 3Department of Infectious Diseases, Landspitali, Reykjavík, Iceland, 4Faculty of Pharmaceutical Sciences, University of Iceland and Hospital Pharmacy, Landspitali, Reykjavík, Iceland, 5Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, 6Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 7Faculty of Medicine, University of Iceland and Department of Science, Landspitali, Reykjavík, Iceland

    Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…
  • Abstract Number: 848 • 2019 ACR/ARP Annual Meeting

    Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis

    Michael George1, Joshua Baker 2, Kevin Winthrop 3, Qufei Wu 2, Lang Chen 4, Fenglong Xie 5, Huifeng Yun 4 and Jeffrey Curtis 4, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA, 3Oregon Health and Science University, Portland, OR, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham

    Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology